EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation

Zhiming Zhang iD, Binfeng Liu iD, Zhengjun Lin iD, Lin Mei iD, Ruiqi Chen iD, Zhihong Li iD

The FASEB Journal · 31.07.2024 · 38 (14)

DOI: 10.1096/fj.202400622rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 22.07.2024. Verfasst von Zhiming Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Osteosarcoma, Osteopontin, Biomarkers, Tumor. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Nature Science Foundation of China, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced survival rates. However, only a few pan‐cancer analyses have targeted SPP1. We conducted a comprehensive analysis using multiple public databases, including TIMER and TCGA, to investigate the expression levels of SPP1 in 33 different tumor types. In addition, we verified the effect of SPP1 on osteosarcoma. To assess the impact of SPP1 on patient outcomes, we employed univariate Cox regression and Kaplan–Meier survival analyses to analyze overall survival (OS), disease‐specific survival (DSS), and progression‐free interval (PFI) in these tumor patients. We also explored SPP1 gene alterations in various tumor tissues using cBioPortal. We then examined the relationship between SPP1 and clinical characteristics, TME, immune regulatory genes, immune checkpoints, TMB, and MSI using R language. In addition, we used GSEA to investigate the molecular mechanisms underlying the role of SPP1. Bioinformatics analysis indicated that SPP1 was upregulated in 17 tumors. Overexpression of SPP1 results in poor OS, DSS, and PFI in CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, and skin cutaneous melanoma. SPP1 expression was positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, and drug sensitivity in certain cancers. We found that high expression of SPP1 in osteosarcoma was related to drug resistance and metastasis and further demonstrated that SPP1 can stimulate osteosarcoma cell proliferation via CCND1 by activating the PI3K/Akt pathway. These findings strongly suggest that SPP1 is a potential prognostic marker and novel target for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaOsteopontinBiomarkers, TumorHumansPrognosisBone NeoplasmsGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

SPP1genetic alternationimmune microenvironmentosteosarcomapan‐cancerprognosis

Substanzen

OsteopontinSPP1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

ORCID-Profile: Zhiming Zhang, Binfeng Liu, Zhengjun Lin, Lin Mei, Ruiqi Chen, Zhihong Li

Förderung

  • The National Nature Science Foundation of China
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Z., Liu, B., Lin, Z., Mei, L., Chen, R., & Li, Z. (2024). SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation. The FASEB Journal, 38(14). https://doi.org/10.1096/fj.202400622rr

Vancouver

Zhang Z, Liu B, Lin Z, Mei L, Chen R, Li Z. SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation. The FASEB Journal. 2024;38(14). doi:10.1096/fj.202400622rr

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhiming and Liu, Binfeng and Lin, Zhengjun and Mei, Lin and Chen, Ruiqi and Li, Zhihong},
  title = {SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {14},
  doi = {10.1096/fj.202400622rr}
}
Kostenlos starten →